Omentin is an adipokine preferentially produced by visceral adipose tissue with insulin-sensitizing effects. Its expression is reduced in obesity, insulin resistance and type 2 diabetes. Omentin is also positively related with adiponectin, high-density lipoprotein levels and negatively related with body mass index, waist circumference, insulin resistance, triglyceride and leptin levels. Lower plasma omentin levels contribute to the pathogenesis of insulin resistance, type 2 diabetes and cardiovascular diseases in obese or overweight patients. Omentin has anti-inflammatory, antiatherogenic, anti-cardiovascular disease and antidiabetic properties. With respect to vascular biology, omentin causes vasodilatation of blood vessels and attenuates C-reactive protein-induced angiogenesis. The ability of omentin to reduce insulin resistance in conjunction with its anti-inflammatory and anti-atherogenic properties makes it a promising therapeutic target. Thus, omentin may have beneficial effects on the metabolic syndrome and could potentially be used as a biologic marker and/or pharmacologic agent/target in this respect.
Keywords: Cardiovascular diseases, diabetes, inflammation, metabolic syndrome, omentin.
Estrogens, a Female Hormone Concerned in Spermatogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization) Editorial (Thematic Issue: Vascular Dysfunction in Obesity and Insulin Resistance)
Current Vascular Pharmacology Natural Substances in the Treatment of Cystic Fibrosis
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Quality of Life of Children with Type 1 Diabetes: A Systematic Review
Current Diabetes Reviews The Potential Implication of FTO rs17817449 Gene Polymorphism on BMI Mediated Risk For Type2 Diabetes Among Obese Egyptian Children And Adolescents
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiovascular and Metabolic Effects of Ghrelin
Current Diabetes Reviews Cancer Therapy Based on a Mechanism of Action for Controlling the Immune System and the Resulting Patent Portfolio
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Under Re-organization) Small Molecule Activators of the Insulin Receptor: Potential New Therapeutic Agents for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Docking, Synthesis and Anti-Diabetic Activity of Novel Sulfonylhydrazone Derivatives Designed as PPAR-Gamma Agonists
Current Topics in Medicinal Chemistry Incretin-Based Therapy of Type 2 Diabetes Mellitus
Current Protein & Peptide Science Prevention of Postprandial Metabolic Stress in Humans: Role of Fruit- Derived Products
Endocrine, Metabolic & Immune Disorders - Drug Targets Development and Characterization of Metformin Loaded Pectin Nanoparticles for T2 Diabetes Mellitus
Pharmaceutical Nanotechnology Systemic Cytokines in Type 2 Diabetes Mellitus and Chronic Periodontitis
Current Diabetes Reviews Evaluation of Specific Immune Responses to BoNT/A and Tetanus Toxoid in Patients Undergoing Treatment for Neurologic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets How Close are We in Achieving Safe, Affordable and Reversible Male Contraceptives?
Endocrine, Metabolic & Immune Disorders - Drug Targets Allergic Contact Dermatitis to Nickel: From Clinical Aspects to Therapeutic Measures
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Structurally Modified Analogues of Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) As Future Antidiabetic Agents
Current Pharmaceutical Design Patent Annotations
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Under Re-organization) Is Type 2 Diabetes Mellitus a Predisposal Cause for Developing Hepatocellular Carcinoma?
Current Diabetes Reviews A Pharmacological Primer of Biased Agonism
Endocrine, Metabolic & Immune Disorders - Drug Targets